AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17915406
Drug: Transdermal regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal regimen
Trial: 15043514
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel (100 mL twice daily for 4 weeks)
Trial: 9110921
Drug: Low-dose beta-hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose beta-hCG (2500-25000 IU/day)
Trial: 9110921
Drug: High-dose beta-hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta-hCG (25000-100000 IU/day)
Trial: 9110921
Drug: Beta-hCG therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-hCG therapy
Trial: 8478852
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMF) treatment for osteoarthritis; 18 half-hour periods of exposure over about 1 month.
Trial: 30678686
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) with combination nutraceutical treatment (CT) 2000 mg/day
Trial: 19414635
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human a-galactosidase A treatment for 5 months
Trial: 19414635
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 5 months
Trial: 15386481
Drug: Almotriptan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 200 mg
Trial: 15386481
Drug: Almotriptan 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 150 mg
Trial: 15386481
Drug: Almotriptan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (various doses 5-200 mg)
Trial: 10092916
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO) treatment: Daily 100-minute treatments with 100% oxygen at 2.8 atmospheres absolute for three days (or six days for clinically abnormal patients).
Trial: 10092916
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen (NBO) treatment: Daily 100-minute treatments with 100% oxygen at 1.0 atmosphere absolute for three days (or six days for clinically abnormal patients).
Trial: 7759785
Drug: Progesterone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone i.m. (50 mg/day)
Trial: 7759785
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal cream (100 mg/day)
Trial: 44124
Drug: Lormetazepam 0.0635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 0.0635 to 0.5 mg/70 kg
Trial: 44124
Drug: Lormetazepam 1
RxNorm normalized name: lormetazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 1 mg/70 kg
Trial: 44124
Drug: Lormetazepam 2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 2‐4 mg/70 kg
Trial: 21910341
Drug: Astragalus treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus treatment (Group A)
Trial: 21910341
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of astragalus and hormone (Group C)
Trial: 16986348
Drug: Bisphosphonates (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (oral and intravenous) such as alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid
Trial: 7756047
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy
Trial: 8776154
Drug: Needle-free injection
RxNorm normalized name: Stratis Needle-Free Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free injection with the Biojector
Trial: 8776154
Drug: Needle and
RxNorm normalized name: syringe with needle and cannula, disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle and syringe injections
Trial: 6130246
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 20 mg/kg body weight (higher dose)
Trial: 6130246
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate 10 mg/kg body weight (lower dose)
Trial: 3525023
Drug: PY 108-068
RxNorm normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PY 108-068 (150 mg)
Trial: 9184390
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg/day
Trial: 16393327
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (twice daily into each nostril for 7 days)
Trial: 6434911
Drug: nasoenteric solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasoenteric solutions
Trial: 29587861
Drug: CoQ10 pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 pre-treatment for 60 days preceding IVF-ICSI cycle
Trial: 27206690
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (3 to 7 spheroids/cm²)
Trial: 27206690
Drug: Medium-dose group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose group (10 to 30 spheroids/cm²)
Trial: 27206690
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (40 to 70 spheroids/cm²)
Trial: 24981149
Drug: Transdermal gel-based
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal gel-based male hormonal contraceptive regimen (testosterone and Nestorone® gels)
Trial: 20447094
Drug: 500-mL water
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mL water drinking test (WDT)
Trial: 20447094
Drug: 1000-mL water
RxNorm normalized name: water 1000 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000-mL water drinking test (WDT)
Trial: 2977393
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amlodipine
Trial: 1737545
Drug: Topical 0.075%
RxNorm normalized name: capsaicin topical 0.075% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.075% capsaicin applied 4 times/day
Trial: 1737545
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied 4 times/day
Trial: 30725092
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone
Trial: 26875224
Drug: Misoprostol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (600 μg oral)
Trial: 12495134
Drug: New measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New measures of the proportion of treatment effect explained by a surrogate marker
Trial: 10088944
Drug: Flow cytometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow cytometry using monoclonal antibodies (HLA‐ABC‐m3, GS145.2, FD705)
Trial: 10088944
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of flow cytometry and DNA typing
Trial: 6361099
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (control group)
Trial: 2349956
Drug: Short-term r‐HuEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term r‐HuEPO therapy (n = 4)
Trial: 2349956
Drug: Long-term r‐HuEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term r‐HuEPO therapy (n = 8)
Trial: 2349956
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (n = 4)
Trial: 2349956
Drug: r‐HuEPO therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO therapy (n = 8)
Trial: 14528103
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg body weight IVIG per day for 2 consecutive days (total dose 2 g/kg)
Trial: 14528103
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg body weight IVIG per day for 2 consecutive days (total dose 0.6 g/kg)
Trial: 10863894
Drug: Serum free
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum free IGF-I levels in children with complete growth hormone deficiencies (cGHD)
Trial: 10863894
Drug: Serum free
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum free IGF-I levels in children with partial growth hormone deficiencies (pGHD)
Trial: 17179251
Drug: Gabapentin 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 1.2 g p.o. before surgery
Trial: 17179251
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules 1 h before surgery
Trial: 8940976
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 micrograms/kg single dose)
Trial: 8940976
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg/day for three days)
Trial: 30811371
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine Patch (NRT)
Trial: 29215395
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.05% as adjuvant therapy to corticosteroids
Trial: 29215395
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment only
Trial: 10321141
Drug: Adjunctive orthognathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive orthognathic surgery
Trial: 12470183
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg per day
Trial: 23735181
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 μg (FP) alone
Trial: 17976289
Drug: Problem-solving treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment for a sub-group of patients with more severe pathology.
Trial: 7943220
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (132 +/‐ 6 pM)
Trial: 3349551
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia combined with light general anaesthesia and postoperative pain relief with intermittent doses of bupivacaine
Trial: 3349551
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia with non-narcotic analgesics
Trial: 25823958
Drug: Secukinumab 10
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 10 mg/kg IV (baseline, weeks 2 and 4)
Trial: 25823958
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg SC (baseline, week 4)
Trial: 25823958
Drug: Secukinumab 10
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 10 mg/kg IV
Trial: 24351993
Drug: Fall prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall prevention program (laughter therapy, exercise, foot care, education), provided once a week for 8 weeks, each session lasting 80 minutes
Trial: 24351993
Drug: Fall prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fall prevention program (laughter therapy, exercise, foot care, education)
Trial: 8984034
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of solutions containing 12 to 36% of calories as protein, 24 to 48% as fat, and 40 to 64% as carbohydrate at 40, 90, or 160 kcal/h for 300 minutes.
Trial: 8984034
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of sodium chloride (9 g/l) added to 16 infusates; osmolality of other 10 infusates was 24 to 98 mOsm.
Trial: 8984034
Drug: Infusions at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions at 40 and 90 kcal/h.
Trial: 2052894
Drug: 0.05% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% chlorhexidine gluconate and 0.04% NaF rinsing solution (CXF)
Trial: 30841655
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of policosanol
Trial: 30841655
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of policosanol
Trial: 21959320
Drug: Clopidogrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel therapy
Trial: 12062320
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg im T enanthate weekly for 8 weeks (eugonadal group)
Trial: 12062320
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg im sodium chloride weekly for 8 weeks (eugonadal control group)
Trial: 12062320
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg im T enanthate biweekly for 8 weeks (hypogonadal group)
Trial: 17146383
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous acetaminophen (Perfalgan)
Trial: 12681003
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 50 mg/day
Trial: 15624081
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 100 mg/day
Trial: 12681003
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg/day (nonobese)
Trial: 12681003
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg/day (obese)
Trial: 15955935
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 600 mg/day
Trial: 10741623
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg three times a day
Trial: 10741623
Drug: Mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 50 mg once a day
Trial: 29656304
Drug: Gentamicin-collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen implant (GCI) applied in the pelvic cavity after total mesorectal excision (TME)
Trial: 29656304
Drug: Gentamicin-collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen implant (GCI)
Trial: 19776646
Drug: Repeat beta-methasone
RxNorm normalized name: beta-Methasone alcohol
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeat beta-methasone (12 mg)
Trial: 15362516
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg TU plus 300 mg DMPA (Group C)
Trial: 7954484
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 mg daily)
Trial: 12932798
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily)
Trial: 29777264
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg or 25 mg once daily
Trial: 22541842
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed mirtazapine tablet formulation
Trial: 22541842
Drug: Established branded
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established branded mirtazapine tablet formulation
Trial: 10795771
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microg bolus intravenous, followed after 2 h by a continuous infusion of 25 microg/hr for 20 hr)
Trial: 10342414
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) patch
Trial: 2149674
Drug: 5, 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5, 10, 20, or 40 mg of fosinopril orally once daily for four weeks
Trial: 2149674
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo orally once daily for four weeks
Trial: 7025264
Drug: Tri-potassium di-citrato
RxNorm normalized name: di-isopropylammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-potassium di-citrato bismuthate (TDB) chewing tablets
Trial: 6397848
Drug: Cimetidine tablets
RxNorm normalized name: Cimetidine Tablets
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine tablets
Trial: 22027686
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet with 5 grams of fish oil daily (omega-6:omega-3 ratio of 2:1)
Trial: 15387158
Drug: Improved treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved treatment adherence
Trial: 6241767
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms HBV vaccine
Trial: 6241767
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms HBV vaccine
Trial: 6241767
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms HBV vaccine
Trial: 23796764
Drug: Baerveldt implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt implant
Trial: 29526236
Drug: Amla (Phyllanthus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amla (Phyllanthus emblica L.) 500 mg tablets, two tablets twice a day for 4 weeks
Trial: 29526236
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets similar to Amla prescription
Trial: 26922847
Drug: Conventional TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional TENS therapy for 20 minutes
Trial: 26922847
Drug: Sham TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TENS therapy
Trial: 23107591
Drug: Fluvirin inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvirin inactivated vaccine
Trial: 23107591
Drug: Fluarix inactivated
RxNorm normalized name: Fluarix 2024-2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix inactivated vaccine
Trial: 20552817
Drug: Complex Decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex Decongestive Therapy (CDT) alone
Trial: 15957137
Drug: High-energy and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy and high-protein supplementation (an extra 475 kcal and 16.6 g of protein daily; group A; n = 12)
Trial: 10444320
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and written instructions
Trial: 7778152
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and 500 mg at 30 h (group A)
Trial: 7778152
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and placebo at 30 h (group B)
Trial: 19297212
Drug: Aspirin (75mg)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (75mg) and cilostazol (100mg twice daily)
Trial: 16176310
Drug: Computer preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer preparation package
Trial: 16176310
Drug: Cartoon preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cartoon preparation package
Trial: 8912110
Drug: Therapeutic community
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic community principles applied in acute care psychiatric treatment program